Thomas Barnes from Intellia Therapeutics gave a talk to Corn Lab

The management and research teams from Intellia Therapeutics came to visit UC Berkeley today. Thomas Barnes, Ph.D., the Senior Vice President of Innovative Sciences & eXtellia, and his teams shared their scientific expertise in CRISPR/Cas9 technology and clinical development experience to the members in Corn lab.

SUBMIT A COMMENT

Your email address will not be published. Required fields are marked *

Filters

Latest News

April 11, 2021

Welcome to Xiaojing

Xiaojing received her Ph.D. from Weill Cornell Graduate School of Medical Science in 2020, working with Dr. Scott Keeney on the mechanism to regulate meiotic...

April 11, 2021

Welcome to Danielle

Danielle received her Ph.D. from Brandeis University in 2021 where she worked with Dr. James Haber to characterize the mechanisms of gene editing via single...

March 29, 2021 -

Moritz awarded a PhD fellowship

Moritz was awarded a Boehringer Ingelheim Fonds (BIF) PhD Fellowship for his project to understand cell type-specific DNA repair preferences during genome...

News Archive

Tweets